BIOVECTRA Inc. Celebrates the Opening of Flagship Warehouse & Process Development Suites as part of Global Biotech Week

Charlottetown, Prince Edward Island (September 21, 2017) – BIOVECTRA Inc. is proud to announce the opening of a new flagship warehouse and process development suites in Charlottetown, Prince Edward Island.

“A vibrant and successful BioScience cluster holds one of the keys to continued growth and prosperity for Canada,” BIOVECTRA’s President Oliver Technow said. “BIOVECTRA is well positioned as a leader in the highly competitive market we participate in, capitalizing on our unique capabilities, 300 tremendously skilled employees and unwavering commitment to quality.”

“The recent and future investments demonstrate our ability to remain competitive and to be at the global forefront of innovation and success, right here in Atlantic Canada,” Technow continued. “Our new, state-of-the-art warehouse meets our business needs of today and the future, exemplifying our dedication to grow further.”

“BIOVECTRA is an excellent example of a company that is constantly adapting to the ever changing technological and scientific landscape in the bioscience industry,” Economic Development and Tourism Minister Heath MacDonald said. “It is a leader in an industry that is growing rapidly, adding new, highly skilled jobs, and gaining an international reputation for our province.”

BIOVECTRA’s grand opening coincides with Global Biotech Week, a Canadian initiative that originated in 2003 to raise awareness of the industry and its global potential.

“Global Biotech Week provides an important opportunity to recognize and celebrate biotechnology innovation and the role it plays in addressing environmental and health challenges,” President and CEO of BIOTECanada Andrew Casey said. “Canada is one of a number of nations that are home to thriving and diverse biotechnology ecosystems which are developing game changing and life altering innovations.”

BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the biotechnology sector.

“BIOVECTRA’s 45 year history, recent growth in Windsor, Nova Scotia and today’s addition of new warehouse and process development suites in Charlottetown, Prince Edward Island is a great example of a made in Canada globally competitive company,” Casey added. “The Canadian biotech ecosystem is supported by strong clusters in every province across the country offering Canadians competitive highly skilled 21st century jobs. All combined, the ecosystem is a strategic economic asset for Canada within the emerging global bio-economy.”

The new 21,000 square foot warehouse enhances BIOVECTRA’s ability to grow with the global demand for its products and services. Equipped with 400 pallet positions, the new warehouse also provides the opportunity to grow with built-in expansions.

“As our business continues to grow, so does the need for storage of our raw materials, consumables and finished products,” BIOVECTRA’s Planning and Operations Manager Tim Murphy said.

With a total investment of $4M, the new warehouse is equipped with a devoted loading dock, dedicated sampling rooms, robust security system and tight temperature controls to keep products at their required temperatures.

About BIOVECTRA

BIOVECTRA is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable partner with a strong quality history, BIOVECTRA has over 45 years of experience specializing in:

Media Contact

Jordan MacGregor
Marketing and Communications Manager
[email protected]
902-566-9116 ext. 6376
www.biovectra.com

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors